Indegene Limited · NSE:INDGN
Indegene — Q1 FY27 Earnings Presentation
21 slides from Indegene's earnings presentation, Jul 30, 2026
Slide 1: Investor Presentation Q1'FY27
Investor Presentation Q1’FY27
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: Quarterly Performance Q1'FY27
Quarterly Performance Q1’FY27 A Quarter of significant growth at scale REVENUE FROM OPERATIONS INR 10,631 M USD 112.5 M ▲ 39.7% ▲ 6.0% ▲ 26.5% ▲ 2.5% YoY in INR QoQ in INR YoY in USD QoQ in USD EBITDA PAT DSO RPE ₹ 1,795 M ₹ 1,162 M 67 Days $ 77.1 K 16.9% of Revenue 10.9% of Revenue ▲ 16.9% YoY ▲ 8.
Slide 4: Revenue Re-Acceleration with Resilient Margins
Revenue Re-Acceleration with Resilient Margins +39.7% 16.9% 10.9% Q1’FY27 Revenue Growth YoY Q1’FY27 EBITDA Margin Q1’FY27 PAT Margin REVENUE (₹ M) EBITDA & PAT MARGIN (%) 10,631 10,034 9,421 8,042 20.2% 7,608 17.6% 17.5% 16.9% 16.4% 15.3% 12.7% 10.9% 10.9% 7.9% Q1'FY26 Q2'FY26 Q3'FY26 Q4'FY26 Q1'FY
Slide 5: Two Growth Engines Driving Revenue Expansion
Two Growth Engines Driving Revenue Expansion Deeper penetration of top accounts and a wider, taller client pyramid are compounding revenue growth G R O W T H A P P R O A C H 1 G R O W T H A P P R O A C H 2 Deeper Engagement with Large Pharma Broader Targeting — Wider, Taller Pyramid ₹7,080M ₹3,231M
Slide 6: Q1'FY27 Business Highlights
Q1’FY27 Business Highlights Expanding customer base | Improving revenue productivity | Strengthening global delivery Customer Growth & Productivity Global Delivery Excellence ACTIVE CLIENT RELATIONSHIPS⁽¹⁾ 105 HEALTHCARE DELIVERY EXPERTISE 29.0% Clients served Share of delivery team with domain skil
Slide 7: Management Commentary on Q1 FY'27 results
Management Commentary on Q1 FY’27 results We started FY27 strongly, delivering sequential USD revenue In Q1FY27, we delivered 39.7% YoY revenue growth in INR terms and growth of 2.5% - our strongest sequential growth in a first 26.5% in USD. We expanded our active client base by 14 sequentially quar
Slide 8: Indegene is a new category – not a better version of an old one
Indegene is a new category – not a better version of an old one Embedded Revenue Partner E • Operate in clients' revenue-generating engine: Commercial & Med teams behind launches, brands & growth $77.1K REVENUE / EMPLOYEE • Sit on growth-side budgets, not IT cost budgets; less exposed to cost-cuttin
Slide 9: Strategic Priorities – FY27
Strategic Priorities – FY27 Going Upstream GenAI Offerings Move up our clients' value chain capturing more of the higher-value work in how they Several of our GenAI offerings have moved from concept to revenue-generating conceive, plan and build commercial and medical activity, building upstream fro
Slide 10: Recognized for Innovation and Excellence (2025-26)
Recognized for Innovation and Excellence (2025-26) Industry Excellence People/ Culture Excellence Global leader in ISG’s 2026 Life Sciences Disruptor in Avasant’s 2026 Life Sciences GPTW India’s Top 50 Best Avtar’s Best Companies for The Great Manager Awards: Digital Services assessment Digital Serv
Slide 11: Financial Highlights
Financial Highlights es ) imdegene
Slide 12: Q1'FY27: Consolidated Financials
Q1’FY27: Consolidated Financials Amount in ₹ M Particulars Q1 FY27 Q4 FY26 Q1 FY26 QoQ % YoY % Revenue from Operations 10,631 10,034 7,608 6.0% 39.7% Employee Benefit Expenses 6,591 6,324 4,815 4.2% 36.9% Other Expenses 2,298 2,074 1,240 10.8% 85.4% Other Income/(loss) 52 13 (17) 312.6% -412.7% EBIT
Slide 13: Q1'FY27: Stable Business mix
Q1’FY27: Stable Business mix Revenue from Service offering ($ M) Revenue by Customer Industry (%)* Revenue by Customer Geography (%) 3.1% 2.0% 88.9 109.7 112.5 3.3% 3.5% 3.0% 3.7% 22.2% 2.2% 75.1% 68.5% 71.7% 70.6% 0.5% 28.0% 25.3% 25.7% 91.6% Q1'FY26 Q4'FY26 Q1'FY27 Enterprise Medical Solutions Bio
Slide 14: Annexure
Annexure i | imdegene’
Slide 15: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Tech-Led Healthcare Delivery and Expertise Digital Capabilities Healthcare market understanding In-depth domain knowledge Digital-first approach GenAI based tools and platform Navigating regulatory landscape Medical content know-how Drive t
Slide 16: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 17: Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation
Full-Stack Capabilities & GenAI Platforms Driving Multi-Quarter Operating Model Transformation Full-Stack, Diverse Capabilities with • Consulting services & management of entire commercial Top 10 and marketing operations in US for a multi-product portfolio Complex Skillsets Omnichannel Pharma • Boos
Slide 18: Dual-Pronged GenAI Strategy
Dual-Pronged GenAI Strategy: Accelerate value for clients today while building for tomorrow Existing Products New Products New Areas/Capabilities Extend capabilities of existing products to capture more value Unlock value from new avenues that have opened up due to EXTEND via cross-sell/up-sell (New
Slide 19: Thank You!
Thank You! www.indegene.com
Slide 20: Fact Sheet
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2027 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth SI. Particulars June 30, Mar 31, June 30, No. YoY QoQ 2026 2026 2025 1. Active clients(1)(No.) 105 91 70 50.0% 15.4% 2. Revenue from operati
Slide 21: Fact Sheet
Fact Sheet Consolidated Financial Data - First Quarter, Fiscal 2027 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars June 30, Mar 31, June 30, YoY QoQ 2026 2026 2025 Biopharma 91.6 89.9 94.1 36.0% 7.9% Medical Devices 3.1 3.9 2.5 74.9% -15.2% Emerging Biotech 3.3 4